Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone353-1634-7800
Debt
Debt-to-Equity Ratio0.55
Current Ratio3.00
Quick Ratio2.88
Price-To-Earnings
Trailing P/E Ratio18.84
Forward P/E Ratio15.46
P/E Growth0.93
Sales & Book Value
Annual Sales$1.62 billion
Price / Sales6.71
Cash Flow$13.0058 per share
Price / Cash13.85
Book Value$45.26 per share
Price / Book3.98
Profitability
EPS (Most Recent Fiscal Year)$9.56
Net Income$487.84 million
Net Margins26.51%
Return on Equity23.78%
Return on Assets11.97%
Miscellaneous
Employees1,210
Outstanding Shares60,290,000
Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions
What is Jazz Pharmaceuticals' stock symbol?
Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
How were Jazz Pharmaceuticals' earnings last quarter?
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported $2.98 EPS for the quarter, topping analysts' consensus estimates of $2.78 by $0.20. The specialty pharmaceutical company had revenue of $444.61 million for the quarter, compared to analyst estimates of $435.69 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. The firm's revenue for the quarter was up 18.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.31 earnings per share. View Jazz Pharmaceuticals' Earnings History.
When is Jazz Pharmaceuticals' next earnings date?
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?
Jazz Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $13.00. The company issued revenue guidance of $1.88-1.93 billion, compared to the consensus revenue estimate of $1.89 billion.
What price target have analysts set for JAZZ?
20 Wall Street analysts have issued 12-month price objectives for Jazz Pharmaceuticals' stock. Their predictions range from $150.00 to $211.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $183.0375 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals.
What are Wall Street analysts saying about Jazz Pharmaceuticals stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Jazz beat expectations for both earnings and sales in Q1. Following improved volume trends of its sleep disorder drug Xyrem in Q1, Jazz raised its future 2018 sales expectations from the drug. Management seems confident that Xyrem will continue to generate volume growth in 2018 and beyond. Jazz’s lead pipeline candidate, JZP-110, is under review in the United States for narcolepsy and OSA and complements its existing sleep disorder portfolio. Meanwhile, its newest drug Vyxeos enjoys improving demand trends following launch in the United States in August 2017. Jazz is also actively evaluating business development deals to enhance its product line and pipeline. Shares of the company have outperformed the industry so far this year. However, Jazz has been facing supply constraints for Erwinaze, due to constrained manufacturing capacity. These supply challenges are expected to continue in 2018." (5/31/2018)
- 2. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018)
- 3. Cantor Fitzgerald analysts commented, "JAZZ’s purchase of PRV makes strategic sense to us. This morning, the acquisition of a Priority Review Voucher (PRV) by JAZZ was disclosed. The company is paying $110 million in cash for a PRV owned by Spark Therapeutics (ONCE, Overweight rated covered by Elemer Piros). Particularly when applied to a speed-to-market situation, we believe the PRV could be useful for JAZZ." (4/30/2018)
Who are some of Jazz Pharmaceuticals' key competitors?
Some companies that are related to Jazz Pharmaceuticals include Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF) and Alnylam Pharmaceuticals (ALNY).
Who are Jazz Pharmaceuticals' key executives?
Jazz Pharmaceuticals' management team includes the folowing people:
- Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
- Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
- Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
- Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)
- Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 55)
Has Jazz Pharmaceuticals been receiving favorable news coverage?
News coverage about JAZZ stock has trended positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Jazz Pharmaceuticals earned a media sentiment score of 0.30 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 45.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Jazz Pharmaceuticals' major shareholders?
Jazz Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.44%), Westfield Capital Management Co. LP (2.01%), Boston Partners (1.78%), FIL Ltd (1.51%), Wells Fargo & Company MN (0.77%) and Amundi Pioneer Asset Management Inc. (0.72%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.
Which institutional investors are selling Jazz Pharmaceuticals stock?
JAZZ stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., American Century Companies Inc., BlackRock Inc., Boston Partners, KBC Group NV, Royal Bank of Canada, Schroder Investment Management Group and Franklin Resources Inc.. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.
Which institutional investors are buying Jazz Pharmaceuticals stock?
JAZZ stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Systematic Financial Management LP, Summit Trail Advisors LLC, LSV Asset Management, Baird Financial Group Inc., Point72 Asset Management L.P., Dimensional Fund Advisors LP and Atlantic Trust Group LLC. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals.
How do I buy shares of Jazz Pharmaceuticals?
Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jazz Pharmaceuticals' stock price today?
One share of JAZZ stock can currently be purchased for approximately $180.13.
How big of a company is Jazz Pharmaceuticals?
Jazz Pharmaceuticals has a market capitalization of $10.87 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.
How can I contact Jazz Pharmaceuticals?
Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]
MarketBeat Community Rating for Jazz Pharmaceuticals (JAZZ)
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
